Central Laboratory, Affiliated Dongguan Hospital, Southern Medical University, Dongguan, China.
Clinical Laboratory, Affiliated Dongguan Hospital, Southern Medical University, Dongguan, China.
Aging (Albany NY). 2021 Oct 29;13(20):23796-23809. doi: 10.18632/aging.203650.
The long intergenic non-coding RNA SNHG7 has been reported to be abnormally expressed in many types of cancer, the results remain controversial. In this study, a meta-analysis was performed to evaluate the clinicopathologic and prognostic value of SNHG7 in cancers. Electronic databases of PubMed, Web of Science, Cochrane Library and Embase were used to search relevant studies. A combined hazard ratio (HR) and its corresponding 95% confidence interval (CI) were used to assess the association between SNHG7 expression and prognosis in cancer patients. Pooled odds ratio (OR) and 95% CI were calculated to elaborate the association between SNHG7 expression and clinicopathological features in cancers. Besides, the data from The Cancer Genome Atlas (TCGA) dataset was used to validate the results. In total, eighteen studies compromising 1303 participants were enrolled in this analysis. The pooled results showed increased SNHG7 expression could predict unfavorable overall survival (OS) (HR = 1.75, 95%CI = 1.52-2.02, P = 0.000). Analysis stratified by follow-up time, cancer types, analysis types, sample sizes and cut off further verified the prognostic value of SNHG7. Additionally, elevated SNHG7 expression was correlated with TNM stage (OR: 3.31, 95%CI = 2.29-4.80, P = 0.000), lymph node metastasis (OR = 3.32, 95%CI = 1.61-6.83, P = 0.004), and tumor differentiation (OR = 1.92, 95%CI = 1.22-3.03, P =0.005) in patients with cancers. Excavation of TCGA dataset valuated that SNHG7 was upregulated in some cancers and predicted worse OS, which partially confirmed our results in this meta-analysis.
长链非编码 RNA SNHG7 在许多类型的癌症中异常表达已有报道，但结果仍存在争议。本研究进行了一项荟萃分析，以评估 SNHG7 在癌症中的临床病理和预后价值。使用 PubMed、Web of Science、Cochrane Library 和 Embase 电子数据库搜索相关研究。使用合并危险比（HR）及其相应的 95%置信区间（CI）来评估 SNHG7 表达与癌症患者预后之间的关系。计算合并优势比（OR）及其 95%CI 来阐述 SNHG7 表达与癌症临床病理特征之间的关系。此外，还使用了癌症基因组图谱（TCGA）数据集的数据来验证结果。总共纳入了 18 项研究，包含 1303 名参与者。汇总结果表明，SNHG7 表达增加可预测不良的总生存期（OS）（HR = 1.75，95%CI = 1.52-2.02，P = 0.000）。按随访时间、癌症类型、分析类型、样本量和截止值进行分层分析进一步验证了 SNHG7 的预后价值。此外，SNHG7 表达升高与 TNM 分期（OR：3.31，95%CI = 2.29-4.80，P = 0.000）、淋巴结转移（OR = 3.32，95%CI = 1.61-6.83，P = 0.004）和肿瘤分化（OR = 1.92，95%CI = 1.22-3.03，P = 0.005）相关。对 TCGA 数据集的挖掘表明，SNHG7 在一些癌症中上调，并预测更差的 OS，这部分证实了我们在本次荟萃分析中的结果。
